Home>Topics>Companies>Gilead Sciences

Gilead Sciences GILD

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Understanding The Excitement That Surrounds Gilead

      Headlines

      Thu, 24 Jul 2014

      By Sam Ross : This article outlines the strengths of Gilead both in the short and long term. I hope to explain the tremendous ..... have outdone themselves. Company Description and Landscape Gilead is a pharmaceutical company focused on creating new treatment

    2. A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval

      Headlines

      Thu, 24 Jul 2014

      By DoctoRx: Gilead Sciences (NASDAQ: GILD ) reported yet another record quarter Wednesday after ..... history by sales. Guidance now includes Sovaldi. From Gilead 's press release : Gilead updated its full-year 2014 guidance, which it initially

    3. Gilead : Even This Raging Bull Was Too Pessimistic

      Headlines

      Thu, 24 Jul 2014

      word that accurately describes the results biotech Gilead Sciences (NASDAQ: GILD ) reported after the bell yesterday. This comes ..... bull on the stock and from an investor who has Gilead as the biggest position in his portfolio. I have

    4. Why Gilead Is A Better Buy Than This Rival

      Headlines

      Thu, 24 Jul 2014

      By Team Money Research : Gilead Background Gilead (NASDAQ: GILD ) is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of life-threatening diseases in North America, South America, Europe

    5. Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences Later This Year

      Headlines

      Thu, 24 Jul 2014

      By Dr. Paul Nunzio De Santis, Pharm.D : Key Takeaways: As anticipated Gilead 's (NASDAQ: GILD ) share price did not respond to the record setting new drug sales of Sovaldi. As we noted in our report the best trading approach

    6. Gilead Sciences - Sovaldi Momentum Continues, Appeal Remains

      Headlines

      Thu, 24 Jul 2014

      By The Value Investor : Gilead Sciences (NASDAQ: GILD ) reported very strong results for the second quarter with ..... stock, or initiate a position. Second Quarter Headlines Gilead posted second quarter revenues of $6.53 billion, up

    7. Gilead : Sovaldi Delivers Q2 Product Sales Of $3.5B... Enough Said

      Headlines

      Thu, 24 Jul 2014

      By Shock Exchange : Picture Of Sovaldi Pills. Source: hepatitiscnewdrugs.blogspot.com Gilead Sciences , Inc . (NASDAQ: GILD ) announced Q2 earnings, and the company delivered... in spades. Total revenues of $6.53 billion

    8. Update: Gilead Sciences Earnings

      Headlines

      Thu, 24 Jul 2014

      By Jason Russ : Gilead Sciences (NASDAQ: GILD ) reported earnings Wednesday ..... my previous article about Gilead titled, " Gilead Sciences : Cause For Concern ..... above, I noted that some Gilead bears feel that the company

    9. Cramer's Mad Money: The 4 Horsemen Trample Big Pharma (7/23/14)

      Headlines

      Thu, 24 Jul 2014

      Trampling Over Big Pharma: Regeneron (NASDAQ: REGN ), Gilead (NASDAQ: GILD ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ ..... Cramer's "Four Horsemen": Regeneron ( REGN ), Gilead ( GILD ), Biogen Idec ( BIIB ) and Celgene ( CELG ). Sales

    10. Gilead Sciences' ( GILD ) CEO John Martin on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Wed, 23 Jul 2014

      Gilead Sciences , Inc . (NASDAQ: GILD ) Q2 2014 Earnings Conference Call July 23, 2014 05:00 PM ET Executives Patrick O'Brien - VP, IR John Martin - Chairman and

    « Prev12345Next »
    Content Partners